## SUPPLEMENTARY FIGURES




**Supplementary Fig. 1: Specificity of the antibodies used in this study. (a)** H3, H4 and huA12 specificity towards soluble CD160 (sCD160) was assessed by ELISA. Each antibody (or its respective isotype control) was used as capture antibody. After incubation with an His-tagged sCD160 fusion protein, revelation was performed using an HRP-conjugated anti-His mAb and TMB substrate. **(b)** Immuno-fluorescence labeling was performed with H3 mAb on wild type or stably transfected CHO or HEK cell lines forced to express either CD160-GPI (CHO) or CD160-TM (HEK) isoform. **(c)** Immuno-staining was performed on CHO-CD160-GPI or HEK-CD160-TM cells using APC-conjugated BY55 or huA12 antibody. Cells were further analyzed by flow cytometry.




**Supplementary Fig. 2: Generation of CD160-depleted WM1361 cell lines. (a)** After transfection with a control plasmid (CTRL) or shCD160-containing plasmid (sh4945 or sh7579) and antibiotic selection, cells were subjected to cell sorting, amplified and analyzed by flow cytometry for their GFP positivity. **(b)** Decreased expression of CD160 was assessed by Western blot using H3 mAb. Equal protein loading was verified through detection of α-actinin.

## SUPPLEMENTARY TABLE:

**Supplementary Table 1: Patients main features (n=16)**

| | |
|---|---|
| Gender (M/F) | 11/5 |
| Age (years) | Mean: 59.25 / Range: 31-81 |
| Stage (n) | III (6), IV (10) |
| Mutational status (n) | WT (7), B-RAF (9) |
| Number of metastatic sites (n) | Mean: 2.3 / Range: 1-5 |
| Treatment at inclusion (n) | Immunotherapy:<br>- Ipilimumab + Nivolumab (10)<br>- Nivolumab (3)<br>Targeted therapy (3)<br>Combo (1) |
| Time of treatment (months) | Mean: 9,75 / Range: 0-55 |
| Response status to treatment (n) | PD (3), PR (10), CR (1), NA (2) |

PD: progressive disease; PR: partial response; CR: complete response; NA: not applicable.